CoChat

Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes

Cusi, Kenneth · 2019 · Hepatology
Cited by 52

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

See Article on Page 2414. Potential conflict of interest: K.C. has received research support as principal investigator from the National Institutes of Health (NIH), Cirius, Echosens, Inventiva, Novartis, Novo Nordisk, Poxel, and Zydus. K.C. is a consultant for Allergan, AstraZeneca, BMS, Boehringer Ingelheim, Coherus, Deuterex, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Poxel, Novo Nordisk, and Sanofi‐Aventis. The prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) is believed to be ~70% and that of advanced fibrosis ~20%.1 Given the magnitude of the problem, there is a real sense of urgency to identify the best pharmacological approach to treat both diabetes and nonalcoholic steatohepatitis (NASH) in this population. Vitamin E is recommended for patients with biopsy‐proven NASH without diabetes,2 but did not have similar efficacy in a recent proof‐of‐concept randomized placebo‐controlled trial (RCT) in patients with T2DM.3 Regarding antidiabetic agents, there is a significant amount of data for some agents, but much more limited information for others.1 Among insulin sensitizers, whereas metformin has not shown significant benefit, pioglitazone has been incorporated into current treatment guidelines for patients with or without T2DM and biopsy‐proven NASH.2 Sodium‐glucose co‐transporter‐2 inhibitors (SGLT2i) promote glycosuria and weight loss, being considered today second‐line therapy for patients with diabetes at risk of cardiovascular disease, heart failure, or chronic kidney disease.6 Promising results have been observed for the treatment of NAFLD in animal models and in open‐label clinical trials.4 Recently, a placebo‐controlled RCT in patients with T2DM reported that canagliflozin promoted weight loss and improved hepatic insulin sensitivity and insulin secretion.7 In those with NAFLD, cangliflozin decreased intrahepatic triglycerides (IHTG) versus baseline, but this was of borderline significance when compared to placebo (−38% vs. −20%; P = 0.09). Of note, all patients received dietary advice at the onset of the trial, which likely caused the positive change in the placebo group. Reduction in IHTG did not appear to be treatment specific, but rather proportional to degree of weight loss, which was more pronounced with canagliflozin (−5.5% vs. −2.1%, respectively; P = 0.001). Patients who did not lose weight had no reduction in IHTG, but more patients on canagliflozin compared to placebo lost ≥5% of body weight and had a ≥30% reduction in IHTG (38% vs. 7%, P = 0.009). This study highlights the importance of lifestyle changes during studies in NAFLD (often even unintended by investigators) and the need for a placebo arm when investigating antidiabetic agents in NAFLD, given that past in vivo animal studies and open‐label clinical trials had suggested unique properties of SGLT2i, beyond weight loss.1 The above serves as an introduction to the role of incretin‐based therapies, the most studied group of all. In animal models of NAFLD, both glucagon‐like peptide‐1 receptor agonists (GLP‐1Ras)8 and dipeptidyl peptidase‐4 inhibitor (DPP‐IVi)10 improve many pathways linked to steatohepatitis, although their efficacy at the clinical level has been mixed (see Tables 1 and 2). In open‐label prospective trials, sitagliptin has been found to improve plasma aminotransferases,12 IHTG,14 and liver histology.15 But negative results have also been reported with sitagliptin in open‐label studies16 and in all three placebo‐controlled trials.18 Negative studies have been also reported with liraglutide,20 but most have been positive with an improvement in hepatic steatosis (HS)22 or liver histology.29 This is usually proportional to the magnitude of weight loss, as reported for other short‐31 and long‐acting32 GLP‐1RAs. However, given the many effects of GLP‐1RAs in animal models of NAFLD, one cannot exclude mechanisms other than weight loss at play. Unfortunately, placebo‐controlled studies with liver biopsies have been rare,20 and the field still awaits the results of large RCTs with GLP‐1RAs (or DPP‐IV inhibitors) using liver histology as the primary outcome, rather than surrogate biochemical or imaging endpoints. Table 1 - Effect of Sitagliptin in NAFLD Author N Duration (Weeks) Comparator Main Study Results Weight ALT Liver Fat (IHTG*) Open‐label studies Iwasaki et al. (2011) 30 16 None Not reported ↓ n/a Ohki et al. (2012) 82 74 Liraglutide, pioglitazone Unchanged ↓ n/a Fukuhara et al. (2014) 44 52 None Not reported Unchanged n/a Asakawa et al. (2015) 62 57 None Not reported Unchanged n/a Kato et al. (2015) 20 24 Glimepiride ↓ Not reported ↓ Alam et al. (2018) 40 52 Lifestyle Unchanged ↓ ↓† Sayari et al. (2018) 138 16 Sitagliptin + synbiotic ↓ ↓ n/a RCTs Smits et al. (2016) 18 12 Liraglutide or placebo Unchanged Unchanged No change vs. placebo Cui et al. (2016) 50 24 Placebo Unchanged Unchanged No change vs. placebo Joy et al. (2017) 12 24 Placebo Unchanged Unchanged No chang

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.30670

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

Metadata

Authors
Cusi, K.
Venue
Hepatology
Published
2019-05-13
Volume
69
Issue
6
Pages
2318-2322
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2937671907
Cited by
52
References
15
FWCI
5.13
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.